Want to see HK:8156 full AI Analyst Report?
Top Page
Sinopharm Tech Holdings Limited
(8156)
Select Model
Select Model
Rating:45Neutral
Price Target:
HK$0.19
▼(-13.18% Downside)
Action:Reiterated
Date:10/16/26
The score is primarily held down by very weak financial performance—sharp revenue decline, ongoing losses, negative equity, and negative recent free cash flow. Technicals offer some near-term stabilization (price above shorter moving averages and RSI in the low 60s), but the longer-term trend remains soft (below the 200-day average) and valuation signals are not supportive given loss-making earnings.
Positive Factors
Debt Reduction
Debt reduction versus prior years is a modest improvement in financial flexibility, potentially lowering future repayment pressure and interest burden. However, this benefit remains limited because debt is still meaningful relative to assets and the company continues to carry negative shareholders’ equity.
Negative Factors
Sharp Revenue Contraction
The steep annual revenue decline indicates substantial deterioration in the company’s current operating scale and weakens visibility into near-term earnings recovery. A shrinking top line also reduces the ability to absorb fixed costs, fund investment, and rebuild sustainable profitability over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt Reduction
Debt reduction versus prior years is a modest improvement in financial flexibility, potentially lowering future repayment pressure and interest burden. However, this benefit remains limited because debt is still meaningful relative to assets and the company continues to carry negative shareholders’ equity.
Read all positive factors
Sinopharm Tech Holdings Limited (8156) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$122.94M
Dividend YieldN/A
Average Volume (3M)24.98K
Price to Earnings (P/E)―
Beta (1Y)0.32
Revenue Growth-25.58%
EPS Growth-12.50%
CountryHK
Employees31
SectorTechnology
Sector Strength88
IndustrySoftware - Application
Share Statistics
EPS (TTM)-0.02
Shares Outstanding633,693,050
10 Day Avg. Volume8,980
30 Day Avg. Volume24,985
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)-2.03
Price to Sales (P/S)2.07
P/FCF Ratio-23.42
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Sinopharm Tech Holdings Limited Business Overview & Revenue Model
Company Description
Sinopharm Tech Holdings Limited functions as an investment holding enterprise, with its primary focus on lottery operations across mainland China and Hong Kong. The company diversifies its activities into several key areas: it supplies both hardwa...
Sinopharm Tech Holdings Limited Financial Statement Overview
Summary
Income Statement
24
Negative
Balance Sheet
10
Very Negative
Cash Flow
22
Negative
| Breakdown | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 45.58M | 61.25M | 41.28M | 42.84M | 40.98M |
| Gross Profit | 6.42M | 13.52M | 5.02M | 5.47M | 5.10M |
| EBITDA | -6.94M | 6.11M | 4.98M | -1.01M | -75.17M |
| Net Income | -9.14M | -867.00K | -19.70M | -10.63M | -88.00M |
Balance Sheet | |||||
| Total Assets | 22.44M | 51.74M | 44.49M | 33.48M | 76.89M |
| Cash, Cash Equivalents and Short-Term Investments | 5.62M | 6.95M | 2.64M | 1.78M | 2.99M |
| Total Debt | 30.73M | 46.73M | 73.26M | 53.00M | 45.93M |
| Total Liabilities | 71.32M | 88.43M | 250.09M | 213.24M | 250.28M |
| Stockholders Equity | -46.40M | -36.87M | -199.48M | -172.73M | -166.78M |
Cash Flow | |||||
| Free Cash Flow | -4.02M | -7.21M | -12.58M | 4.73M | -36.88M |
| Operating Cash Flow | -4.02M | -7.21M | -9.25M | 4.73M | -36.76M |
| Investing Cash Flow | 2.00K | -9.00K | -4.86M | 2.00K | -85.00K |
| Financing Cash Flow | 3.07M | 11.50M | 14.98M | -4.52M | 32.24M |
Sinopharm Tech Holdings Limited Technical Analysis
Negative
0.22
Price Trends
0.19
Negative
0.19
Positive
0.23
Negative
Market Momentum
>-0.01
Negative
48.92
Neutral
49.05
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:8156, the sentiment is Negative. The current price of 0.22 is above the 20-day moving average (MA) of 0.19, above the 50-day MA of 0.19, and below the 200-day MA of 0.23, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 48.92 is Neutral, neither overbought nor oversold. The STOCH value of 49.05 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:8156.
Sinopharm Tech Holdings Limited Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $37.18B | 12.37 | -10.20% | 1.83% | 8.50% | -7.62% | |
59 Neutral | HK$2.35B | 10.81 | 7.63% | 3.63% | 16.99% | 126.15% | |
58 Neutral | HK$1.49B | 82.44 | 21.60% | ― | 151.97% | ― | |
54 Neutral | HK$2.17B | 344.72 | 0.76% | ― | -2.29% | -91.48% | |
47 Neutral | HK$2.33B | -30.39 | -5.91% | ― | ― | ― | |
45 Neutral | HK$122.94M | -7.39 | 20.88% | ― | -25.58% | -12.50% |
* Technology Sector Average
HK:8156
Sinopharm Tech Holdings Limited
0.19
-0.11
-35.33%
HK:8148
Aurum Pacific (China) Group Ltd.
3.25
1.22
60.10%
HK:9885
YSB Inc.
3.44
-5.64
-62.10%
HK:2576
Zhejiang Taimei Medical Technology Co Ltd Class H
4.14
-0.28
-6.33%
HK:2571
Beijing Saimo Technology Co. Ltd. Class H
16.25
3.41
26.56%
HK:6687
JST Group Corporation Limited
9.85
-24.79
-71.56%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.